F3

Tissue factor · P13726 · F3 on Sugi Atlas →

129,069 patent compounds predicted against F3, 92,878 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Stevioside (SCHEMBL33428)	0.41	9/20
Stevioside (SCHEMBL33429)	0.41	9/20
Linolenic Acid (SCHEMBL15282)	1.00	7/20
Icosapent (SCHEMBL20469)	1.00	7/20
Docosapentaenoic Acid (SCHEMBL20748)	1.00	7/20
SCHEMBL25423	1.00	7/20
SCHEMBL37141	1.00	7/20
SCHEMBL37142	1.00	7/20
Linolenic Acid (SCHEMBL46586)	1.00	7/20
Linolenic Acid (SCHEMBL51037)	0.96	7/20
Linolenic Acid (SCHEMBL104457)	0.96	7/20
Linolenic Acid (SCHEMBL106610)	0.96	7/20
Linolenic Acid (SCHEMBL106701)	0.96	7/20
SCHEMBL29226	0.96	7/20
Linolenic Acid (SCHEMBL105730)	0.90	7/20
Linolenic Acid (SCHEMBL106808)	0.79	7/20
SCHEMBL105841	0.53	7/20
SCHEMBL91182	0.80	6/20
Oleic Acid (SCHEMBL1138)	1.00	5/20
Oleic Acid (SCHEMBL1139)	1.00	5/20

Clinical trials — most relevant to F3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）	PHASE4	RECRUITING
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock	PHASE2/PHASE3	COMPLETED
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	PHASE3	COMPLETED
Fibrinogen Early In Severe Trauma StudY II	PHASE3	RECRUITING
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A	PHASE3	COMPLETED
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes	PHASE2	COMPLETED
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome	PHASE2	COMPLETED
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B	PHASE2	COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome	PHASE1	COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System	PHASE1	COMPLETED
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
Tissue Factor Expression in Stage C Heart Failure	nan	COMPLETED
Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital	nan	NOT_YET_RECRUITING
Coagulation After Intravenous Methylprednisolone Administration	nan	COMPLETED
PROgnostic Value of MicroParticles and Markers of Hemostasis in TIA and Ischemic Stroke	nan	COMPLETED
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion	nan	RECRUITING
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock	nan	COMPLETED
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia	nan	COMPLETED
Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement	nan	RECRUITING
The Roles of Tissue Factor in Malignant Gliomas	nan	COMPLETED
Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010	nan	UNKNOWN
TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects.	nan	COMPLETED
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer	nan	UNKNOWN
Are Uterine Fibroids Pro-thrombotic?	nan	ACTIVE_NOT_RECRUITING
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects	nan	UNKNOWN
Heparin Management During Cardiopulmonary Bypass in Children	nan	COMPLETED
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function	nan	UNKNOWN
Liver Biopsy In Haemophilia Gene Therapy	nan	RECRUITING
Effects of Desflurane Versus Propofol on Hemostasis During Splenectomy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a F3 binder may also engage these)

Protein	Name	Similarity
P24055	—	1.000	P24055 →
P30931	—	1.000	P30931 →
Q9JLU8	—	0.992	Q9JLU8 →
P42533	—	0.986	P42533 →
P20352	—	0.986	P20352 →
O09030	—	0.983	O09030 →
P78552	—	0.983	P78552 →
Q00560	—	0.982	Q00560 →
P40190	—	0.981	P40190 →
Q5XNR9	—	0.981	Q5XNR9 →
Q8NI17	—	0.981	Q8NI17 →
Q99650	—	0.980	Q99650 →
P42703	—	0.979	P42703 →
K7NAJ3	—	0.979	K7NAJ3 →
P21183	—	0.979	P21183 →
IFNAR1	Interferon alpha/beta receptor 1	0.977	landscape →
O70535	—	0.977	O70535 →
Q8JZL1	—	0.977	Q8JZL1 →
Q9NRM6	—	0.977	Q9NRM6 →
K7NA32	—	0.977	K7NA32 →
Q01344	—	0.977	Q01344 →
Q9JIP3	—	0.976	Q9JIP3 →
Q9HC73	—	0.976	Q9HC73 →
P43303	—	0.976	P43303 →
LIFR	Leukemia inhibitory factor receptor	0.976	landscape →
Q90369	—	0.976	Q90369 →
Q98936	—	0.976	Q98936 →
P38484	—	0.975	P38484 →
Q01638	—	0.975	Q01638 →
P97710	—	0.975	P97710 →